Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Commentary

Commentary on “Non-Steroidal Anti-inflammatory Drugs Loaded Liposomes for Topical Treatment of Inflammatory and Degenerative Conditions” by Carla Matos, FP-ENAS-UFP Energy, Environment and Health Research Unit/CEBIMED-Centro de Estudos em Biomedicina, Fernando Pessoa University, Porto, Portugal Challenges and Prospects of Topical Treatment of Inflammatory and Degenerative Conditions: A Vesicular Approach

Author(s): Maha Nasr*

Volume 27, Issue 27, 2020

Page: [4577 - 4578] Pages: 2

DOI: 10.2174/092986732727200619175649

« Previous
[1]
Nasr, M.; Abdel-Hamid, S. Optimizing the dermal accumulation of a tazarotene microemulsion using skin deposition modeling. Drug Dev. Ind. Pharm., 2016, 42(4), 636-643.
[http://dx.doi.org/10.3109/03639045.2015.1062512] [PMID: 26133080]
[2]
Nasr, M.; Abdel-Hamid, S.; Moftah, N.H.; Fadel, M.; Alyoussef, A.A. Jojoba oil soft colloidal nanocarrier of a synthetic retinoid: preparation, characterization and clinical efficacy in psoriatic patients. Curr. Drug Deliv., 2017, 14(3), 426-432.
[http://dx.doi.org/10.2174/1567201813666160513132321] [PMID: 27174314]
[3]
Abdelgawad, R.; Nasr, M.; Moftah, N.H.; Hamza, M.Y. Phospholipid membrane tubulation using ceramide doping “Cerosomes”: characterization and clinical application in psoriasis treatment. Eur. J. Pharm. Sci., 2017, 101, 258-268.
[http://dx.doi.org/10.1016/j.ejps.2017.02.030] [PMID: 28232140]
[4]
Bseiso, E.A.; Nasr, M.; Sammour, O.; Abd El Gawad, N.A. Recent advances in topical formulation carriers of antifungal agents. Indian J. Dermatol. Venereol. Leprol., 2015, 81(5), 457-463.
[http://dx.doi.org/10.4103/0378-6323.162328] [PMID: 26261140]
[5]
Amer, S.S.; Nasr, M.; Mamdouh, W.; Sammour, O. Insights on the use of nanocarriers for acne alleviation. Curr. Drug Deliv., 2019, 16(1), 18-25.
[http://dx.doi.org/10.2174/1567201815666180913144145] [PMID: 30210000]
[6]
Hatem, S.; Nasr, M.; Moftah, N.H.; Ragai, M.H.; Geneidi, A.S.; Elkheshen, S.A. Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils. Expert Opin. Drug Deliv., 2018, 15(10), 927-935.
[http://dx.doi.org/10.1080/17425247.2018.1517740] [PMID: 30169980]
[7]
Hatem, S.; Nasr, M.; Elkheshen, S.A.; Geneidi, A.S. Recent advances in antioxidant cosmeceutical topical delivery. Curr. Drug Deliv., 2018, 15(7), 953-964.
[http://dx.doi.org/10.2174/1567201815666180214143551] [PMID: 29446743]
[8]
Ramez, S.A.; Soliman, M.M.; Fadel, M.; Nour El-Deen, F. Novel methotrexate soft nanocarrier/fractional erbium YAG laser combination for clinical treatment of plaque psoriasis Artif. Cells Nanomed. Biotechnol., 2018, 46(sup1), 996-1002.
[http://dx.doi.org/10.1080/21691401.2018.1440236] [PMID: 29448838]
[9]
Nasr, M.; Mansour, S.; Mortada, N.D.; Elshamy, A.A. Vesicular aceclofenac systems: a comparative study between liposomes and niosomes. J. Microencapsul., 2008, 25(7), 499-512.
[http://dx.doi.org/10.1080/02652040802055411] [PMID: 18608811]
[10]
Bsieso, E.A.; Nasr, M.; Moftah, N.H.; Sammour, O.A.; Abd El Gawad, N.A. Could nanovesicles containing a penetration enhancer clinically improve the therapeutic outcome in skin fungal diseases? Nanomedicine (Lond.), 2015, 10(13), 2017-2031.
[http://dx.doi.org/10.2217/nnm.15.49] [PMID: 26135513]
[11]
Hatem, S.; Nasr, M.; Moftah, N.H.; Ragai, M.H.; Geneidi, A.S.; Elkheshen, S.A. Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: design, characterization and clinical appraisal. Eur. J. Pharm. Sci., 2018, 122, 246-253.
[http://dx.doi.org/10.1016/j.ejps.2018.06.034] [PMID: 29981403]
[12]
Fadel, M.; Samy, N.; Nasr, M.; Alyoussef, A.A. Topical colloidal indocyanine green-mediated photodynamic therapy for treatment of basal cell carcinoma. Pharm. Dev. Technol., 2017, 22(4), 545-550.
[http://dx.doi.org/10.3109/10837450.2016.1146294] [PMID: 26895257]
[13]
Matos, C.; Lobão, P. Non-steroidal anti-inflammatory drugs loaded liposomes for topical treatment of inflammatory and degenerative conditions. Curr. Med. Chem., 2020, 27(23), 3809-3829.
[http://dx.doi.org/10.2174/0929867326666190227233321] [PMID: 30827226]
[14]
Budhiraja, A.; Dhingra, G. Development and characterization of a novel antiacne niosomal gel of rosmarinic acid. Drug Deliv., 2015, 22(6), 723-730.
[http://dx.doi.org/10.3109/10717544.2014.903010] [PMID: 24786487]
[15]
Yang, D.; Pornpattananangkul, D.; Nakatsuji, T.; Chan, M. The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials, 2009, 30(30), 6035-6040.
[http://dx.doi.org/10.1016/j.biomaterials.2009.07.033] [PMID: 19665786]
[16]
Marianecci, C.; Rinaldi, F.; Di Marzio, L.; Mastriota, M. Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models. Int. J. Nanomedicine, 2014, 9, 635-651.
[http://dx.doi.org/10.2147/IJN.S55066] [PMID: 24493924]
[17]
Marianecci, C.; Rinaldi, F.; Mastriota, M.; Pieretti, S.; Trapasso, E.; Paolino, D.; Carafa, M. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J. Control. Release, 2012, 164(1), 17-25.
[http://dx.doi.org/10.1016/j.jconrel.2012.09.018] [PMID: 23041542]
[18]
Zesch, A. Clinical regulatory aspects of topical liposomal drugs with special consideration of safety aspects., 1992,Liposome Dermatics, 288-296.
[http://dx.doi.org/10.1007/978-3-642-48391-2_30]
[19]
Metselaar, J.M.; Storm, G. Liposomes in the treatment of inflammatory disorders. Expert Opin. Drug Deliv., 2005, 2(3), 465-476.
[http://dx.doi.org/10.1517/17425247.2.3.465] [PMID: 16296768]
[20]
Hua, S.; Dias, T.H.; Pepperall, D.G.; Yang, Y. Topical loperamide-encapsulated liposomal gel increases the severity of inflammation and accelerates disease progression in the adjuvant-induced model of experimental rheumatoid arthritis. Front. Pharmacol., 2017, 8, 503.
[http://dx.doi.org/10.3389/fphar.2017.00503] [PMID: 28824428]

© 2024 Bentham Science Publishers | Privacy Policy